Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06612541

Point-of-Care Ophthalmic Diagnostic Imaging of Retinopathy of Prematurity

Status
Recruiting
Phase
Study type
Observational
Enrollment
90 (estimated)
Sponsor
Vanderbilt University Medical Center · Academic / Other
Sex
All
Age
24 Weeks – 34 Weeks
Healthy volunteers
Not accepted

Summary

The goal of this proposal is to develop novel HH-SECTR technology for visualizing and quantifying diagnostic disease features in prematurely born infant retinopathy of prematurity (ROP) patients that lead to more informed clinical decision making. Providing depth-resolved vascular information has not been adequately investigated for its diagnostic potential. Furthermore, we seek to identify disease features not currently accessible by standard examination methods to better inform clinical decisions.

Detailed description

Imaging studies using HH-SECTR will be performed to assess and quantify structural and vascular disease features associated with ROP. Weekly HH-SECTR imaging will be performed concurrently with standard-of-care weekly ROP screening. No additional treatments will be given to study patients to benefit HH-SECTR imaging (e.g., sedation, dilation, etc.). Study patients will primarily be imaged in the NICU, but may also be performed under sedation or anesthesia in the operating room concurrent with standard-of-care exams. Because this study will evaluate diagnostic features prognostic of ROP progression and severity, HH-SECTR imaging will be performed until 45 weeks, cessation of ROP screening, or first therapeutic intervention, whichever comes first. Both eyes will undergo HH-SECTR imaging. Diagnostic imaging data will be analyzed following each imaging session. No experimental data will be used to alter the management of patients from the standard-of-care. Research materials obtained from subjects will include digital HH-SECTR images, digital fundus photography images, and documented examination timeline as part of the standard-of-care. Patient medical records will be used to determine eligibility to participate in the study and will be used as the source documents for following post-examination clinical variables. The duration of the study will be 5 years. The study records and information will be indefinitely archived per NIH rules using the methods noted above.

Conditions

Timeline

Start date
2025-02-01
Primary completion
2029-02-01
Completion
2030-02-01
First posted
2024-09-25
Last updated
2025-05-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06612541. Inclusion in this directory is not an endorsement.